Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes

Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes

Abstract Background Dysferlinopathies are a group of muscle disorders causing muscle weakness and absence or low levels of dysferlin, a type-II transmembrane protein and the causative gene of these dystrophies. Dysferlin is implicated in vesicle fusion, trafficking, and membrane repair. Muscle biops...

Full description

Bibliographic Details
Main Authors: Esther Fernández-Simón, Cinta Lleixà, Xavier Suarez-Calvet, Jordi Diaz-Manera, Isabel Illa, Eduard Gallardo, Noemí de Luna
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Musculoskeletal Disorders
Subjects:
Dysferlin
Proteasome
Vitamin D3
Myogenin
Sarcolemma
Thrombospondin-1
Online Access:https://doi.org/10.1186/s12891-020-03756-7

Internet

https://doi.org/10.1186/s12891-020-03756-7

Similar Items